Information de reference pour ce titreAccession Number: | 00001716-201301000-00006.
|
Author: | Shiah, H.-S. 1 2 3; Chen, C.-Y. 2; Dai, C.-Y. 4; Hsiao, C.-F. 5; Lin, Y.-J. 6; Su, W.-C. 2; Chang, J.-Y. 1 2; Whang-Peng, J. 1 7; Lin, P.-W. 6; Huang, J.-D. 8; Chen, L.-T. 1 2 4 8
|
Institution: | (1) National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (2) Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan (3) Department of Internal Medicine, Division of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan (4) Department of Internal Medicine and Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan (5) Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan (6) Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan (7) Cancer Center Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (8) Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
|
Title: | |
Source: | Alimentary Pharmacology & Therapeutics. 37(1):62-73, January 2013.
|
Abstract: | Background: Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC).
Aim: To determine the maximum tolerated dose (MTD) of the oral mTOR inhibitor everolimus in advanced HCC patients.
Methods: Patients with locally advanced or metastatic HCC (Child-Pugh class A or B) were enrolled in an open-label phase 1 study and randomly assigned to daily (2.5-10 mg) or weekly (20-70 mg) everolimus in a standard 3 + 3 dose-escalation design. MTD was based on the rate of dose-limiting toxicities (DLTs). Secondary endpoints included safety, pharmacokinetics and tumour response. In a post hoc analysis, serum hepatitis B virus (HBV) DNA levels were quantified.
Results: Thirty-nine patients were enrolled. DLTs occurred in five of 21 patients in the daily and two of 19 patients in the weekly cohort. Daily and weekly MTDs were 7.5 mg and 70 mg respectively. Grade 3/4 adverse events with a >=10% incidence were thrombocytopenia, hypophosphataemia and alanine transaminase (ALT) elevation. In four hepatitis B surface antigen (HBsAg)-seropositive patients, grade 3/4 ALT elevations were accompanied by significant (>1 log) increases in serum HBV levels. The incidence of hepatitis flare (defined as ALT increase >100 IU/mL from baseline) in HBsAg-seropositive patients with and without detectable serum HBV DNA before treatment was 46.2% and 7.1% respectively (P < 0.01, Fisher exact test). Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.
Conclusions: The recommended everolimus dosing schedule for future hepatocellular carcinoma studies is 7.5 mg daily. Prophylactic anti-viral therapy should be mandatory for HBsAg-seropositive patients (ClinicalTrials.gov NCT00390195).
Copyright (C) 2013 Blackwell Publishing Ltd.
|
References: | 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010; 127: 2893-917.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007; 132: 2557-76.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012; 379: 1245-55.
4. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther, 2006; 23: 1535-47.
5. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2012. 2012. Available at: http://- ouverture dans une nouvelle fenêtre www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed April 16, 2012.
6. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. Eur J Cancer, 2012; 48: 599-641.
7. Kanwal F, Befeler A, Chari RS, et al. Potentially curative treatment in patients with hepatocellular cancer-results from the liver cancer research network. Aliment Pharmacol Ther, 2012; 36: 257-65.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008; 359: 378-90.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009; 10: 25-34.
10. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006; 441: 424-30.
11. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 2004; 10: 8421-5.
12. Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation, 2007; 83: 425-32.
13. Varma S, Khandelwal RL. Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70(S6K) in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB. Biochim Biophys Acta, 2007; 1770: 71-8.
14. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 2002; 8: 128-35.
15. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol, 2007; 46: 840-8.
16. Huynh H, Chow KH, Soo KC, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med, 2009; 13: 1371-80.
17. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 2008; 135: 1972-83.
18. Zaghla H, Selby RR, Chan LS, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther, 2006; 23: 513-20.
19. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl, 2012; 18: 62-9.
20. Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther, 2001; 70: 425-30.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000; 92: 205-16.
22. Liu SF, Hsieh MH, Hou NJ, et al. Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int, 2010; 4: 601-7.
23. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol, 2008; 26: 1588-95.
24. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol, 2010; 40: 17-23.
25. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol, 2008; 26: 1603-10.
26. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 2011; 117: 5094-102.
27. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010; 116: 4256-65.
28. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011; 364: 514-23.
29. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med, 2012; 366: 520-9.
30. Poon RTP, Finn RS, Yau T, et al. Everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma. Hong Kong: Presented at the 5th Annual Conference of the International Liver Cancer Association, 2-4 Sep, 2011.
31. Piguet AC, Saar B, Hlushchuk R, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther, 2011; 10: 1007-17.
32. Hoofnagle JH. Reactivation of hepatitis B. Hepatology, 2009; 49: S156-65.
33. Stypmann J, Engelen MA, Eckernkemper S, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Munster. Transplant Proc, 2011; 43: 1847-52.
34. Guo H, Zhou T, Jiang D, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol, 2007; 81: 10072-80.
35. Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology, 2011; 54: 1199-207.
36. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology, 1991; 13: 150-7.
37. Benner KG, Lee RG, Keeffe EB, Lopez RR, Sasaki AW, Pinson CW. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology, 1992; 103: 1307-12.
38. Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology, 1992; 102: 956-62.
39. Meuleman P, Libbrecht L, Wieland S, et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol, 2006; 80: 2797-807.
40. Jung S, Lee HC, Han JM, et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol, 2002; 17: 345-50.
41. Schoniger-Hekele M, Muller C. Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment Pharmacol Ther, 2010; 32: 763-8.
42. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol, 2008; 13: 66-70.
43. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol, 2002; 20: 1527-36.
|
Language: | English.
|
Document Type: | Randomised Clinical Trial: RANDOMISED CLINICAL TRIALS.
|
Journal Subset: | Clinical Medicine. Pharmacology.
|
ISSN: | 0269-2813
|
NLM Journal Code: | a5d, 8707234
|
DOI Number: | https://dx.doi.org/10.1111/apt.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|